Drug intelligence / Profile preview

Allogeneic Microbiota in Glycerol

Development stage: Phase 2
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral, Rectal

Overview

Allogeneic Microbiota in Glycerol (AMG) is a microbiome therapy consisting of fecal microbiota from healthy donors preserved in glycerol. It is designed to restore gut microbiota diversity and function in patients with disrupted intestinal microbiomes. AMG has shown approximately 60-90% efficacy for decolonization of multidrug-resistant organisms (MDROs) with an acceptable safety profile. This therapy represents a form of fecal microbiota transplantation (FMT) that aims to restore colonization resistance and gut barrier function through the introduction of diverse commensal bacteria.

Other names: allogeneic microbiota-Emory University-multidrug resistant organism colonizationfecal microbiota transplant

Beyond the preview

Go deeper on Allogeneic Microbiota in Glycerol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Allogeneic Microbiota in Glycerol.

Explore the full profile